{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-215435","form_type":"8-K","ticker":"PEPG","cik":"0001835597","company_name":"PepGen Inc.","filed_at":"2025-09-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.228297+00:00","generated_at":"2026-05-17T05:48:33.424445+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"PepGen reports 53.7% mean splicing correction in DM1 patients at 15 mg/kg dose","bullets":["Mean splicing correction of 53.7% at 15 mg/kg (n=6) by 22-gene panel at Day 28; all 6 patients responded.","PGN-EDODM1 well-tolerated; no serious treatment-related AEs, all mild/moderate, transient, resolved without intervention.","Dose-proportional muscle concentration increase vs 5 mg/kg (12.3%) and 10 mg/kg (29.1%) cohorts.","FREEDOM2 MAD study 5 mg/kg cohort data expected Q1 2026; 10 mg/kg cohort dosing to begin Q1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-215435","json":"https://secwatch.observer/filing/0001193125-25-215435.json","markdown":"https://secwatch.observer/filing/0001193125-25-215435.md","text":"https://secwatch.observer/filing/0001193125-25-215435.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835597/000119312525215435/0001193125-25-215435-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835597/000119312525215435/d67598d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:48:33.424445+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}